Imago BioSciences

Imago BioSciences is a biotechnology company based in South San Francisco, California. The company employs 38 people and generates $2.5 million in annual revenue. Imago BioSciences focuses on developing drugs to treat proliferative diseases of the bone marrow. Their research concentrates on acute myeloid leukemia, myelodysplastic syndrome, polycythemia vera, myelofibrosis, and essential thrombocythemia. These diseases are characterized by acquired mutations in blood stem cells, leading to excessive bone marrow cell growth and altered function. The company's approach involves developing inhibitors of the enzyme lysine-specific demethylase 1 (LSD1), which plays a crucial role in regulating bone marrow cell growth and development. Their lead clinical inhibitor, bomedemstat (IMG-7289), is currently being investigated in patients with acute myeloid leukemia, myelodysplastic syndrome, and myeloproliferative neoplasms, including myelofibrosis. For more information, visit Imago BioSciences' website at imagobio.com.